Skip to main content
CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
22.37
+0.85 (3.95%)
At close: Apr 25, 2025, 4:00 PM
30.78
+8.41 (37.59%)
Pre-market: Apr 28, 2025, 8:51 AM EDT

CG Oncology Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
1.140.20.1910.36
Revenue Growth (YoY)
458.33%6.81%-98.16%-
Cost of Revenue
82.145.7529.0318.32
Gross Profit
-80.96-45.55-28.84-7.96
Selling, General & Admin
33.79.96.414.65
Operating Expenses
33.79.96.414.65
Operating Income
-114.67-55.45-35.25-12.61
Interest Expense
---0-0.45
Interest & Investment Income
26.626.91.6-
Other Non Operating Income (Expenses)
0-0.06-1.8-0.18
EBT Excluding Unusual Items
-88.04-48.61-35.44-13.24
Other Unusual Items
---0.4
Pretax Income
-88.04-48.61-35.44-12.84
Net Income
-88.04-48.61-35.44-12.84
Preferred Dividends & Other Adjustments
-19.198.355.54
Net Income to Common
-88.04-67.8-43.79-18.38
Shares Outstanding (Basic)
62444
Shares Outstanding (Diluted)
62444
Shares Change (YoY)
1343.03%15.77%2.48%-
EPS (Basic)
-1.41-15.65-11.71-5.04
EPS (Diluted)
-1.41-15.65-11.71-5.04
Free Cash Flow
-78.95-45.68-29.82-13.75
Free Cash Flow Per Share
-1.26-10.55-7.97-3.77
Gross Margin
----76.86%
Operating Margin
-10067.25%-27180.88%-18453.40%-121.70%
Profit Margin
-7729.50%-33234.31%-22925.65%-177.48%
Free Cash Flow Margin
-6931.26%-22391.67%-15611.52%-132.76%
EBITDA
-114.63-55.43-35.23-12.6
EBITDA Margin
----121.61%
D&A For EBITDA
0.030.020.020.01
EBIT
-114.67-55.45-35.25-12.61
EBIT Margin
----121.70%
Updated Mar 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q